secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-08-03T20:09:43+00:00
Accession:  0000875320-26-000256
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q2 revenue $3.33B (+12% YoY); raises FY revenue guidance to $13.1-13.2B; announces $10B Crinetics acquisition
--------------------------------------------------------------------------------

- Total revenue $3.33B, up 12% YoY; GAAP net income $1.1B, non-GAAP $1.2B.
- Full-year 2026 revenue guidance raised to $13.1-13.2B from $12.95-13.1B.
- CASGEVY revenue $76M (+151% YoY); JOURNAVX revenue $50M (quadrupled YoY).
- Entered agreement to acquire Crinetics for $85/share, total equity value ~$10B; close expected Q3 2026.
- Povetacicept PDUFA date Nov 30, 2026 for IgAN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/0000875320-26-000256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer